Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Matthew J. Cotter"'
Autor:
Dmitry I. Gabrilovich, Ji-Hyun Lee, Bhupendra Rawal, Karen T. Liby, Michael B. Sporn, Scott Antonia, Mayer Fishman, Carlos R. Becerra, Colin Meyer, Matthew J. Cotter, Lily Lu, Cristina Iclozan, Hannah Weber, Je-In Youn, Srinivas Nagaraj
Supplementary Data from Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcf02a6b966399f455c3be3999b58867
https://doi.org/10.1158/1078-0432.22442984
https://doi.org/10.1158/1078-0432.22442984
Autor:
Dmitry I. Gabrilovich, Ji-Hyun Lee, Bhupendra Rawal, Karen T. Liby, Michael B. Sporn, Scott Antonia, Mayer Fishman, Carlos R. Becerra, Colin Meyer, Matthew J. Cotter, Lily Lu, Cristina Iclozan, Hannah Weber, Je-In Youn, Srinivas Nagaraj
Purpose: Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify effective therapeutic means to modulate these cells.Experimental Design: We evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754fcf863b7be5a65ae611d96ca7c4a6
https://doi.org/10.1158/1078-0432.c.6519602.v1
https://doi.org/10.1158/1078-0432.c.6519602.v1
Autor:
Ajay K, Gopal, Rakesh, Popat, Ryan J, Mattison, Tobias, Menne, Adrian, Bloor, Terry, Gaymes, Asim, Khwaja, Mark, Juckett, Ying, Chen, Matthew J, Cotter, Ghulam J, Mufti
Publikováno v:
International Journal of Hematologic Oncology
Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. Patients & methods: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monothe
Autor:
Ariel B. Bourla, Zhe Zhang, Cynthia Huang Bartlett, Christina M. Parrinello, Jack Mardekian, Xin Huang, Matthew J. Cotter
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0227256 (2020)
PLoS ONE
PLoS ONE
There is growing interest in leveraging real-world data to complement knowledge gained from randomized clinical trials and inform the design of prospective randomized studies in oncology. The present study compared clinical outcomes in women with met
Autor:
Keith L. Davis, S Nagar, Vered Stearns, Lynn McRoy, Matthew J. Cotter, Adam Brufsky, Debanjali Mitra
Publikováno v:
Cancer Research. 78:P5-21
Background: The objective of this study was to evaluate treatment patterns and clinical outcomes among patients who received palbociclib in combination with letrozole (P+L) for the treatment of HR+/HER2–advanced breast cancer (ABC) as part of an Ex
Autor:
AP Abernethy, Zhe Zhang, M Koehler, Xin-Yun Huang, Jack Mardekian, CM Parrinello, Cynthia Huang Bartlett, Matthew J. Cotter
Publikováno v:
Cancer Research. 78:P3-17
Background: There is growing interest to assess treatment effect with clinical endpoints that are reflective of real world clinical practice based on data systemically collected from the electronic health record (EHR). This study compared real world
Publikováno v:
Cancer Research. 76:P4-13
Background: In the Phase I/II PALOMA-1 trial, a study in women with estrogen receptor (ER) positive advanced breast cancer (ABC) receiving initial therapy for their metastatic disease, combination of the CDK4/6 inhibitor palbociclib with letrozole im
Autor:
Adam, Brufsky, Debanjali, Mitra, Keith L, Davis, Saurabh P, Nagar, Lynn, McRoy, Matthew J, Cotter, Vered, Stearns
Publikováno v:
Clinical breast cancer. 19(5)
To evaluate treatment patterns and clinical outcomes of patients who received palbociclib in combination with letrozole in any line of therapy for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic br
Autor:
Vered Stearns, Debanjali Mitra, Matthew J. Cotter, Adam Brufsky, Keith L. Davis, Lynn McRoy, Saurabh P Nagar
Publikováno v:
Clinical Breast Cancer. 19:317-325.e4
Purpose To evaluate treatment patterns and clinical outcomes of patients who received palbociclib in combination with letrozole in any line of therapy for treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative m
Autor:
David Cheong, G. Douglas Letson, Brianna Lenox, Cristina Iclozan, Ricardo J. Gonzalez, Claudia Berman, Steven E. Finkelstein, Rupal Ramakrishnan, Scott J. Antonia, Vernon K. Sondak, David Noyes, Jamil Ahmed, William J. Janssen, Dmitry I. Gabrilovich, Jonathan S. Zager, Randy V. Heysek, Marilyn M. Bui, Matthew J. Cotter
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 82:924-932
Purpose The goal of this study was to determine the effect of combination of intratumoral administration of dendritic cells (DC) and fractionated external beam radiation (EBRT) on tumor-specific immune responses in patients with soft-tissue sarcoma (